Dr. Daniel L. King |
Daniel L. King , MD
Curriculum Vitae
Practice Experience
July 2001 to Present Arthritis and Joint Center of Florida
Melbourne, Florida
1985 to July 2001 Brevard Orthopaedic Clinic
Melbourne, Florida
Practice Specialty
Adult Reconstructive Surgery including joint replacement and arthroscopic surgery.
Medical Licensure
Licensed by the State of Florida since October, 1982
Board Certification
American Board of Orthopaedic Surgery
Certified July 1987
Re-certified October 1996
Hospital Privileges
Health First Holmes Regional Medical Center
1985 to Present Active Staff
1990 to 1993 Chairman Department of Orthopaedics
1998 to 1999 President of Medical Staff
1998 to 1999 Board Member HRMC
HEALTHSOUTH Sea Pines Rehabilitation Hospital
Active Staff
Past President of Medical Staff
Wuesthoff Hospital Melbourne
Active Staff
Memberships
Brevard County Medical Society
Florida Medical Association
American Medical Association
Fellow, American Academy of Orthopaedic Surgeons
Florida Orthopaedic Society
Fellow, American College of Physician Executives
Honors
Alpha Omega Alpha, Medical Honorary Society 1980
Education
1999 Florida Institute of Technology
Melbourne, Florida
Masters of Business Administration
1985 University of South Florida affiliated hospitals, Tampa. Florida
Resident in Orthopaedic Surgery
Specialty training in Adult Reconstruction, Kenneth Gustke, M.D.
Trauma Orthopaedics, Jeffrey Mast, M.D.
Program Chairman, Philip Spiegel, M.D.
1980 University of South Florida College of Medicine,
Tampa, Florida
Doctor of Medicine
1976 University of Florida, Gainesville, Florida
Bachelor of Science, Zoology
Clinical Research
Orthobiotech, Inc. (Procrit Vigor Study), Protocol pr99-19-019
“Clinical Evaluation of Perioperative Hemoglobin and the Relationship to Postoperative Vigor in Patients undergoing Total Joint Arthroplasty”
1/19/1999 – 10/19/2000
Sanofi (Pentasaccharide Study), Protocol EFC 2442 “A Multi Center, Multinational, Double-Bind Comparison of Subcutaneous SR90107A/Org31540 with Enoxaparin in the Prevention of Deep Vein Thrombosis and Symptomatic Pulmonary Embolism after Elective Hip Replacement” 4/22/1999 – 11/10/1999
Emisphere Technology/Auintiles, (Oral Heparin Study) “The Protect Trial”, Protocol ERP 12/3 to ERP 12/4 “A Radomized, Double-Blind, Multi Center Study Comparing the Safety and Efficacy of Two Dosing Regimens of Oral Emisphere SNAC/Heparin with Subcutaneous Enoxaparin Sodium for the Presentation of Venous Thromboembolic Events” 1/15/2000 – 11/16/2000
Prospective, Randomized, FDA approved, Metal Bearing Total Hip, Implex Corporation, Protocol IC001-99, “Performance of the Implex Hedocel Metal Bearing Total Hip Replacement System in Primary Total Hip Arthroplasty” 10/1999 - Present
Prospective, Consecutive, Total Knee Outcomes Study, Utilizing Hedrocel Mono block Tibia, Implex Corporation, 6/2000 - Present
> back to top of page
|
